Kromek is pioneering digital colour imaging for x-rays and has brought ground-breaking innovation to materials technology and advanced 3D imaging, that will literally change the way in which we see the world.


The Company specialises in making semiconductor materials within the Cadmium Telluride family. These materials have significant applications as detectors of x-rays and gamma rays, notably in medical imaging, security screening, industrial inspection and space exploration, allowing for very precise identification of materials.



Cadmium Zinc Telluride is also the material of choice as a substrate for the fabrication of infrared detectors in both civilian and military markets. In addition to its range of semiconductor materials, detector packages and non imaging detection systems Kromek also supplies x-ray imaging packages with multi view capabilities.

These x-ray display platforms provide real 3D x-ray imaging for the first time without specialist viewing equipment. When photogrammetric algorithms are applied to these images, three dimensional co-ordinate data is produced.

Kromek Group is listed on London's alternative Investment Market, AIM. Its ordinary shares carry the symbol KMK. Kromek Group plc is incorporated in England and Wales under the Companies Act 2006 (registration number 8661469). Its main countries of operation are the United Kingdom and the United States.

http://www.kromek.com/

UPDATE - Kromek sees greater demand

By Jamie Ashcroft

August 28 2014, 2:36pm
Kormek won significant contracts in the medical imaging market
Kormek won significant contracts in the medical imaging market


--Adds broker comment--

Kromek (LON:KMK) revealed it is seeing greater demand for its products.

The technology firm in today’s results, for the twelve months to April 30, highlighted multiple significant contract wins in the medical imaging market and agreements to supply imaging modules to China.

It also agreed contracts with both commercial and government customers for nuclear detection.

"The appetite for Kromek's components, systems and solutions in each of our target markets is increasing,” said chief executive Arnab Basu.

“The group is well placed, not only to continue to win new contracts, but also to service the growing demand for our technologies and achieve our ambition of becoming the radiation detection specialists of choice in our chosen markets.

“We have reported a number of new contracts post this period end and we are continuing to convert a strong pipeline with the current order book at an all-time high."

Panmure Gordon analyst Dr Mike Mitchell said Kromek performed ‘in line’ as he upgraded his recommendation to ‘buy’ from ‘hold.

In a note the analyst said: “While a business such as Kromek will always be subject to some element of temporal risk (such as timing on government expenditure), we believe the broader commercial positioning and a greater emphasis on budgeting/planning stands the business in good stead.”

On AIM, Kromek shares moved 0.4p (0.8%) lower at 50.1p.

Interim Results
RNS
RNS Number : 0947C
Kromek Group PLC
14 January 2015



14 January 2015



Kromek Group plc

("Kromek" or the "Company")



Interim Results



Kromek (AIM: KMK), a radiation detection technology company focusing on the medical, security and nuclear markets, announces its interim results for the six months ended 31 October 2014.



Financial Highlights

· Revenue increased 33% to £3.2m (H1 2013/14: £2.4m)

· Adjusted EBITDA* improved to £1.6m loss (H1 2013/14: £2.0m loss)

· Loss before tax was £2.3m (H1 2013/14: £2.5m loss)

· Gross margin** was 70% (H1 2013/14: 61%)

· Loss per share was 1p (H1 2013/14: 9p loss)

· Cash and cash equivalents at 31 October 2014 were £2.86m (30 April 2014: £6.56m; 31 October 2013: £9.96m), with no debt and the Company expects to be EBITDA positive for the second half of the current financial year



*Adjusted EBITDA eliminates non-recurring other income, share-based payment expenses. See 'Financial Review' below for a reconciliation of adjusted EBITDA.

**As with prior periods, gross margin is calculated before labour and overhead recovery.



Operational Highlights

· Progress achieved across all of Kromek's target sectors of medical imaging, nuclear detection and security screening, with increased sales of the Company's product portfolio while developing products and enhancing customer engagements in medical CT, SPECT and portable networkable radiation detectors

· Revenue growth as a result of higher nuclear and security product sales and US Government contracts, and supplemented by contracts with OEMs in medical imaging and sale of bottle scanners

· Successfully progressed to second year of exclusive development programme in medical CT market with a top four global OEM

· Awarded significant new opportunity by US Defense Advanced Research Projects Agency ("DARPA") with project to develop advanced portable detection system for gamma and neutron radiation that can be combined in large networks

· Key contracts won in US and UK with US Defense Threat Reduction Agency ("DTRA") and Innovate UK

· Significant contract awarded for providing bottle scanner technology to a number of airports in Asia. Over 40 airports in 10 countries now using Kromek bottle scanners

· Doubled cadmium zinc telluride ("CZT") crystal manufacturing capacity by expanding in UK, and demonstrated ability to rapidly scale up production by successfully replicating the manufacturing process previously being conducted only in US

· 10 new patents were granted and 18 new patent applications were filed during the period



Post-Period Developments

· Awarded a number of significant contracts across the business:

o $1.0m contract extension by leading global security company for developing CZT-based detectors for medical and nuclear markets, including homeland security

o First contract from another global security technology group and market leader in security solutions

o Further contract by existing customer for OEM components for baggage screening

o First contract from a leading global healthcare and diagnostics company for development of bone mineral densitometry ("BMD") applications

o Additional $1.1m contract by DARPA, as announced today, for enhancing the continued development of advanced networkable radiation detectors

· Nine patents were granted post period



Dr Arnab Basu, CEO of Kromek, said: "We are pleased to report another half year of growth against the comparative period as a result of sustained progress in Kromek's product portfolio approach whilst advancing our strategy of becoming the preferred component supplier to major OEMs in CT and SPECT and in the supply of network sensors in nuclear markets. This has been achieved both by establishing new partnerships and strengthening our existing relationships.



"Looking ahead, investment in enhancing our sales and marketing function is resulting in increased interest in Kromek's products and technology from a greater number of companies and organisations. We continue to be subject to fluctuations in the timing of certain contracts and revenue recognition as well as the impact of seasonality, with the procurement cycle of many customers resulting in sales being weighted to the second half of the current financial year. Despite this, the Company remains confident that it can deliver in excess of 100% revenue growth from the first half to second half of the current financial year. Additionally, the Company expects to be EBITDA positive for the second half of this year."

MIDAS-SHARE-TIPS-Kromek-s-scanners-stop-make-bomb.

Up 10% today.

MEET THE TECH SUPERSTARS OF TOMORROW

A 12-month share price performance of the companies that presented at the Innovators & Investors Forum last year included:

Elecosoft +42%
Idox +22%
Instem +34%
KBC Advanced +45%
XL Media +41%

The Innovators & Investors Forum, organised in partnership with Cenkos Securities and SHARES, is in its 4th year and is the UK's only technology investment show.

REGISTER NOW

Thousands of investors have attended our previous shows, attendees will also benefit from:

Learning from industry experts and influencers about the markets, the technology sector and individual companies
Find out from fund managers how they view the future in 2016
Meet the directors of up to 30 listed technology focused companies
Listen to our expert team of SHARES journalists

The event is supported with an extensive conference program
Keynote Speakers:

Daniel Coatsworth, Editor - Shares
Mark Dunne, Growth Companies Reporter - SHARES
Steven Frazer, Online Editor - SHARES
Russ Mould, Investment Director - AJ Bell
Richard Penny, Senior Fund Manager - Legal & General UK Alpha Trust
Simon Strong, Head of Research, Growth Companies - Cenkos Securities
Gervais Williams, MD - Miton Group

Further speakers to be announced soon.

Meet the teams and talk directly to CEOs and Directors from:


Advanced Oncotherapy
Abzena
Advanced Oncotherapy
ANGLE
Brady
CML Microsystems
Cyan
Eckoh
eg solutions
Flowgroup
Ilika
Instem
Kromek
Lombard Risk
Mirada
Plastics Capital
Quantum Pharma
Rosslyn Data Technologies
Selftrade
SHARES
TyraTech

Further companies to be announced soon.




Date: 2nd February 2016

Venue: Business Design Centre, London


Event timings

Registration: from 09:00
Conference: 09:45 - 17:00
Exhibition: 09:00 - 18:00



REGISTER NOW

Strong buying all week.

Oh dear, Needs more contract wins.

Director/PDMR Shareholding
RNS
RNS Number : 8156A
Kromek Group PLC
29 March 2017
 
29 March 2017
 
Kromek Group plc
("Kromek" or the "Company")
 
Director/PDMR Shareholding
 
 
Kromek (AIM: KMK), a radiation detection technology company focusing on the medical, security and nuclear markets, announces that it has received notification that, on 24 March 2017,  Berry Beumer, Chief Operating Officer of Kromek, purchased 80,000 Ordinary Shares of 1 pence each ("Ordinary Shares") in the Company at a price of 29.35 pence per share.
 
Following the purchase, Mr. Beumer has an interest in 80,000 Ordinary Shares representing 0.03% of the entire current issued share capital of the Company.

Solid buying today, looking for a bounce.

Trading Update
RNS
RNS Number : 6251D
Kromek Group PLC
28 April 2017
 
28 April 2017
 
Kromek Group plc
("Kromek" or the "Company" or the "Group")
 
Trading Update
 
Kromek, a radiation detection technology company focusing on the medical, security and nuclear markets, provides the following trading update for the year ending 30 April 2017 ahead of its full year results to be issued in July 2017.
 
The Group is making good progress on the delivery of new orders won over the past two years and, as a result, the Company is trading in line with market expectations.  
 
The Group's products continue to gain traction in all its business segments from the increasing adoption of CZT-based technology and other products. The Group expects to continue to win new customers and, together with the momentum of contract wins, it expects a step change in revenue growth in the new financial calendar year.

Good trades gone through today, due another jump.

Good 11% rise today, 34p + would be a good start.

Kromek Radiation Detectors Used During Trump Visit
RNS
RNS Number : 7432H
Kromek Group PLC
12 June 2017
 
 
12 June 2017
 
Kromek Group plc
("Kromek" or the "Company")
 
Kromek's Radiation Detectors Used by the European Commission Counter Terrorism Unit During President Trump's Visit to Brussels
 
Kromek (AIM: KMK), a radiation detection technology company focusing on the medical, security screening and nuclear markets, is pleased to announce that its next generation standalone radiation detector, D3S-ID, was deployed by European Commission Counter Terrorism Unit of Directorate General for Home Affairs in Brussels. The D3S-ID was part of security operations deployed during the NATO Security Summit and the U.S. President, Donald Trump's visit to Brussels last month.
 
The European Commission and Belgian Federal Police officers deployed D3S-ID at different locations including Brussels airport and the European Council headquarters.  Kromek was informed that the deployment was successful and its radiation detection systems performed well and met the desired high standards for accuracy and efficiency.
 
Dr Arnab Basu, Chief Executive Officer of Kromek, said: "We are delighted to be part of the security system that was deployed during President Trump's visit to Brussels. Specifically, we were pleased that the deployment was successful and that our detectors achieved the necessary high standards. We look forward to continuing our work with the European Commission, DARPA and other national law enforcement agencies to deploy our best-of-breed radiation detectors to protect people and property."
 

Await news

Reached 36.5p today, before settling at 34.88p

Going to motor, pdyor.

I've put it on my watchlist!😃

:-))

Final Results
RNS
RNS Number : 3547J
Kromek Group PLC
28 June 2017
 
28 June 2017
 
Kromek Group plc
("Kromek" or the "Group")
 
Final Results for the Year ended 30 April 2017
 
Kromek (AIM: KMK), a radiation detection technology company focusing on the medical, security screening and nuclear markets, announces its final audited results for the year ended 30 April 2017.
 
Financial Highlights
·     Revenue increased 7.5% to £9.0m (2015/16: £8.3m)
·     Product sales accounted for 74% of total revenues (2015/16: 65%), a growth year-on-year of 23%
·     Gross margin was 57% (2015/16: 53%)
·     Administration costs (including operating expenses) were £8.7m (2015/16: £8.3m)
·     EBITDA* was £1.5m loss (2015/16: £2.4m loss), following further investment of £3.5m (2015/16: £3.2m) of research costs expensed in preparation for the expected demand regarding D3S and SPECT
·     Loss before tax for the year was £3.8m (2015/16: £4.1m loss)
·     Total proceeds of £21m (£20m net of expenses) were raised as part of a Placing and Open Offer in February 2017, which saw a further 105,129,536 ordinary shares issued 
·     Cash and cash equivalents at 30 April 2017 were £20.3m (30 April 2016: £3.9m)
*EBITDA defined as earnings before interest, taxation, depreciation, amortisation and share-based payments.
 
Operational Highlights
Another year of good progress and ramp-up in commercial activities with revenue growth driven by higher product sales across Kromek's three key target markets.
 
Medical Imaging 
·     Commenced delivery on $12.6m five-year OEM contract to supply detectors for BMD diagnostics systems
·     Awarded repeat contracts by three current BMD customers worth $1.2m in total
·     Won contract worth minimum of $560,000 for the supply of radiation detectors with an existing customer
·     Continued to make progress on the development of CZT-based SPECT modules for customer in China
 
Nuclear Detection
·     Delivered 10,000 D3S units in support of DARPA's SIGMA programme
o D3S sensors were field-tested in Washington DC and currently deployed by New Jersey Port Authority
·     Awarded $1.6m two-year agreement from DTRA to develop a ruggedised high performance isotope radiation detector for military use
·     Won and delivered a $430,000 contract to supply nuclear radiation detection products to the UK Ministry of Defence
 
Security Screening
·     Secured five-year agreement, worth a minimum of $3.1m, from an existing US-based customer
·     Awarded 12-month contract, valued at $990,000, together with a ten-year exclusivity agreement, by an existing US-based customer to develop and supply upgraded detectors
·     Awarded and delivered a contract for the Group's bottle scanners from an Asian airport group 
 
Six new patents were filed and 11 granted during the period.
 
Dr Arnab Basu, CEO of Kromek, said: "We are pleased with the growth in revenues this year, reflecting the delivery of long-term contracts won in previous years and contracts won during the year. Kromek is at the leading-edge in developing commercially-viable radiation detection solutions and this has, in turn, enabled our customers to successfully launch their new generation of clearly differentiated products in a wide range of markets. Consequently, revenues from the sale of our products now accounts for nearly three quarters of our revenues.
 
"In the 2017/18 fiscal year, Kromek is seeing a step change across all its business segments as we continue to execute on the large-scale contracts that have been secured over the last 24 months. Additionally, we expect OEM customers to launch products incorporating our technology, prompting additional orders to be placed as sales of these products accelerate. As a result, the Group expects to report year-on-year revenue growth of approximately 40%, in-line with market expectations."

Out before close, not good enough.